Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
28.27
+0.61 (2.21%)
Mar 6, 2026, 4:00 PM EST - Market closed
Assembly Biosciences Employees
Assembly Biosciences had 73 employees as of December 31, 2024. The number of employees increased by 8 or 12.31% compared to the previous year.
Employees
73
Change (1Y)
8
Growth (1Y)
12.31%
Revenue / Employee
$509,466
Profits / Employee
-$528,041
Market Cap
447.15M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| REGENXBIO | 353 |
| 4D Molecular Therapeutics | 227 |
| Entrada Therapeutics | 152 |
| Niagen Bioscience | 104 |
| Solid Biosciences | 100 |
| Lineage Cell Therapeutics | 77 |
| Anavex Life Sciences | 34 |
ASMB News
- 2 months ago - Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes - Business Wire
- 3 months ago - Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript - Seeking Alpha
- 3 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 4 months ago - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 4 months ago - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting® - GlobeNewsWire
- 5 months ago - Assembly Biosciences Announces Upcoming Investor Conference Participation - GlobeNewsWire
- 5 months ago - Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe - GlobeNewsWire
- 5 months ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga